Objective: To examine outcomes associated with colesevelam treatment among patients with hypercholesterolemia in real-world clinical practice.
Methods: This analysis was conducted as a retrospective, observational cohort study in an ambulatory-care medical network in Northern California. Patients with orders for colesevelam were identified in the electronic health record between January 2004 and December 2011. The date of the first order during the study period was designated the index date. Patients were evaluated for the following eligibility criteria: a diagnosis of hypercholesterolemia, ≥18 years of age at index date, baseline laboratory values ≤3 months before the index date, ≥12 months of treatment and follow-up, and no prior orders for colesevelam ≤12 months before the index date. Patients who were pregnant during the study period were excluded. Changes in LDL-C and percentage of patients at LDL-C goal were examined. Among patients with diabetes mellitus (DM), changes in glycated hemoglobin (HBA1C) and percentage of patients at HBA1C goal were also examined.
Results: Overall, 468 and 181 patients with hypercholesterolemia met the predefined inclusion criteria with treatment and follow-up through 12 and 24 months, respectively. LDL-C decreased significantly from baseline by a mean of 11.4 mg/dL and 15.7 mg/dL (P < 0.0001, for each) at 12 and 24 months, respectively, and the percentages of patients at LDL-C goal increased by 13.9% and 21.0%. Among patients with DM and a baseline HBA1C ≥8%, 113 and 39 had treatment and follow-up through 12 and 24 months, respectively. HBA1C decreased significantly by a mean of 0.72% (P = 0.0001) and 0.75% (P = 0.010) and 11.5% and 12.8% were at HBA1C goal at 12 and 24 months, respectively. This study is limited by its retrospective and observational study design.
Conclusions: Colesevelam treatment in a real-world setting was associated with improvements in LDL-C and HBA1C through 24 months of follow-up.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1185/03007995.2013.842162 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment of bile acid diarrhea with GLP-1 receptor agonists: A Promising Yet Understudied Approach.
Clin Transl Gastroenterol
January 2025
Center for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.
Bile acid diarrhea (BAD) is a chronic and socially debilitating disease characterized by abdominal pain, diarrhea, urgency, and fecal incontinence. Recently, in a six-week randomized controlled trial (RCT), we showed that the glucagon-like peptide 1 receptor agonist (GLP-1RA) liraglutide is superior to bile acid sequestration (considered standard-of-care) using colesevelam in reducing BAD symptoms. The emergence of new, more potent, and longer-acting GLP-1RAs has spurred an interest in these treatments in BAD management.
View Article and Find Full Text PDFLiraglutide and Colesevelam Change Serum and Fecal Bile Acid Levels in a Randomized Trial With Patients With Bile Acid Diarrhea.
Clin Transl Gastroenterol
November 2024
Center for Clinical Metabolic Research, Copenhagen University Hospital-Herlev and Gentofte, Hellerup, Denmark.
Introduction: Both liraglutide and colesevelam improve bile acid diarrhea symptoms. Colesevelam binds excess amounts of diarrhea-causing bile acids in the colon, whereas the mode of action for liraglutide remains elusive. In this article, we examined the impact of colesevelam and liraglutide treatment on the concentrations of bile acids in serum and feces and the fecal microbiota composition to better understand the 2 drugs' modes of action.
View Article and Find Full Text PDFEfficacy of Bile Acid Sequestrants in the Treatment of Bile Acid Diarrhea: A Meta-Analysis of Randomized Controlled Trials.
J Clin Pharmacol
October 2024
Metropolitan University of Santos, Santos, São Paulo, Brazil.
Bile acid sequestrants (BASs) have often been used for bile acid diarrhea (BAD) but carry a high risk of adverse events. New generations of BASs show promising results; however, their efficacy remains unclear. This systematic review and meta-analysis was conducted using PubMed, Cochrane, and Embase to assess randomized controlled trials (RCTs) published up to November 2023 to retrieve studies that measured the parameters before and after the administration of BASs.
View Article and Find Full Text PDFThe Effect of Colesevelam on the Microbiome in Postoperative Crohn's Disease.
Inflamm Bowel Dis
October 2024
Department of Gastroenterology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK.
Background: While surgery plays a pivotal role in the management of ileal Crohn's disease, the risk of endoscopic recurrence following an ileocaecal resection can be greater than 65% within 12 months of surgery. More than 90% of patients with Crohn's disease have a concomitant diagnosis of bile acid diarrhea following an ileal resection. This pilot study aimed to assess whether the use of bile acid sequestrants in patients with Crohn's disease who have undergone a primary terminal ileal resection with concomitant bile acid diarrhea can alter the microbiome and prevent disease recurrence.
View Article and Find Full Text PDFMicroscopic Colitis: An Underestimated Disease of Growing Importance.
J Clin Med
September 2024
Department of Digestive Tract Disease, Medical University of Lodz, 90-647 Lodz, Poland.
Article Synopsis
- The paper aims to increase awareness of microscopic colitis (MC), a chronic inflammatory bowel disease, focusing on its recognition, risk factors, diagnosis, management, and complications.
- MC is characterized by nonspecific symptoms like watery diarrhea, which makes diagnosis challenging, and the average onset age is around 62-65 years, with women being more affected.
- Risk factors for MC include lifestyle factors like smoking and alcohol consumption, various medications, and other health conditions; treatment typically involves budesonide or other therapies tailored to individual cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!